|
| Type of Sickle | Total | |||||
| Hb SB + thalassemia | Hb SB 0-thalassemia | Hb SC | Hb SS | SCT | |||
| Arterial phase | Well Enhanced Lesion& Calcifications | 1 (3.1%) | 3 (9.4%) | - | 1 (3.1%) | - | 5 (15.6%) |
| Well Enhanced Nodules | 1 (3.1%) | - | - | 1 (3.1%) | - | 2 (6.3%) | |
| Well Enhanced Cysts | - | - | 1 (3.1%) | - | - | 1 (3.1%) | |
| Heterogeneous Enhancement | - | - | - | 2 (6.3%) | 1 (3.1%) | 3 (9.4%) | |
| Ring Enhancement | - | - | - | 1 (3.1%) | - | 1 (3.1%) | |
| Peripheral Enhancement with Ill Enhanced Lesion | - | - | - | 3 (9.4%) | - | 3 (9.4%) | |
| Ill Enhanced Lesion | - | 2 (6.3%) | 4 (12.5%) | 6 (18.8%) | - | 12 (37.5%) | |
| Not Enhanced | - | - | 1 (3.1%) | 4 (12.5%) | - | 5 (15.6%) | |
| Total | 2 (6.3%) | 5 (15.6%) | 6 (18.8%) | 18 (56.3%) | 1 (3.1%) | 32 (100.0%) | |
| P-value = 0.085 | |||||||